Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
My View
Tags:

Barr receives ANDA approval for two erythromycin compounds

  • News

Executive Summary

Barr's ANDAs for erythromycin delayed-release 333 mg capsule shaped and round shaped tablets were approved May 16, and its ANDA for erythromycin stearate 500 mg taba was approved May 15. Bar already markets erythromycin stearate 250 mg tabs. Barr will be the first generic firm to to sell erythromycin delayed-release 333 mg tab as a multisource product. Boots' E-Mycin and Abbott's Ery-Tab are marketed as branded versions of erythromycin delayed-release 333 mg and 250 mg tabs. Barr has alleged that FDA has intentionally delayed approval of its erythromycin delayed-release ANDAs as well as other applications in order to retaliate against the firm for testifying about problems with FDA's Division of Generic Drugs. FDA has told Barr that it must conduct a second bioequivalence study for its pending ANDA for a 250 mg tab. Barr received ANDA approval for the 500 mg tab in November 1988.

Table

View full table

Tags:
Latest Headlines

Recent And Upcoming FDA Advisory Committee Meetings

Mismatch Between Growing Vaccine Pipeline and CDC’s ACIP Capacity

Keeping Track: Two Breakthrough Oncologics, Another Antibiotic Clear US FDA Along With Pfizer’s Hemophilia B Gene Therapy

Priority Review Vouchers: Tropical Disease Candidates Wait Years For FDA Action On Qualifying List

See All
UsernamePublicRestriction

Register

PS017488

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By